efavirenz and Aging

efavirenz has been researched along with Aging in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cottrell, M; Dumond, JB; Forrest, A; Francis, O; Hudgens, MG; Malone, S; Mollan, K; Patterson, KB; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; Van Dam, C; Wang, R; White, N	1
Antunes, MV; Linden, R; Menezes, AM; Poeta, J; Real, L; Ribeiro, JP; Sprinz, E	1
Allard, C; Cassuto, JP; Chene, G; De Castro, N; Garré, M; Journot, V; Molina, JM; Rancinan, C; Sobel, A; Vildé, JL	1

Trials

1 trial(s) available for efavirenz and Aging

Article	Year
Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jun-15, Volume: 42, Issue:12 Topics: Adult; Aging; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depressive Disorder; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Risk Factors; Suicide	2006

Article

Year

Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jun-15, Volume: 42, Issue:12

Topics: Adult; Aging; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depressive Disorder; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Risk Factors; Suicide

2006

Other Studies

2 other study(ies) available for efavirenz and Aging

Article	Year
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy. Antiviral therapy, 2016, Volume: 21, Issue:5 Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclin-Dependent Kinase Inhibitor p16; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Ritonavir; Tenofovir; Young Adult	2016
Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:11 Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4 Lymphocyte Count; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Viral Load	2011

Article

Year

Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.

Antiviral therapy, 2016, Volume: 21, Issue:5

Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclin-Dependent Kinase Inhibitor p16; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Ritonavir; Tenofovir; Young Adult

2016

Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.

The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:11

Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4 Lymphocyte Count; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Viral Load

2011